{"pmid":32319081,"title":"Delivering extracorporeal membrane oxygenation for patients with COVID-19: what, who, when and how?","text":["Delivering extracorporeal membrane oxygenation for patients with COVID-19: what, who, when and how?","On 11 March 2020, the World Health Organization (WHO) declared novel coronavirus disease 2019 (COVID-19), caused by severe respiratory syndrome coronavirus-2 (SARS-CoV-2), a worldwide pandemic. Although most patients with SARS-CoV-2 are asymptomatic or experience only mild disease, approximately 14% develop severe disease associated with a high case fatality rate [1-3]. Patients with severe respiratory failure refractory to tracheal intubation, positive pressure ventilation, prone positioning, deep sedation, neuromuscular blockade and other conventional strategies might be considered for venovenous extracorporeal membrane oxygenation (VV-ECMO).","Anaesthesia","Zochios, V","Brodie, D","Charlesworth, M","Parhar, K K","32319081"],"abstract":["On 11 March 2020, the World Health Organization (WHO) declared novel coronavirus disease 2019 (COVID-19), caused by severe respiratory syndrome coronavirus-2 (SARS-CoV-2), a worldwide pandemic. Although most patients with SARS-CoV-2 are asymptomatic or experience only mild disease, approximately 14% develop severe disease associated with a high case fatality rate [1-3]. Patients with severe respiratory failure refractory to tracheal intubation, positive pressure ventilation, prone positioning, deep sedation, neuromuscular blockade and other conventional strategies might be considered for venovenous extracorporeal membrane oxygenation (VV-ECMO)."],"journal":"Anaesthesia","authors":["Zochios, V","Brodie, D","Charlesworth, M","Parhar, K K"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319081","week":"202017|Apr 20 - Apr 26","doi":"10.1111/anae.15099","keywords":["covid-19","decision-making","extracorporeal membrane oxygenation","ventilation"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087662137344,"score":8.518259,"similar":[{"pmid":32313662,"pmcid":"PMC7161844","title":"Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan.","text":["Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan.","Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is one of the ultimate treatments for acute respiratory failure. However, the effectiveness of ECMO in patients with novel coronavirus disease (COVID-19) is unknown. Case Presentation: A 72-year-old woman who was a passenger of a cruise ship tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while in quarantine on board using throat swab. Three days after admission, her condition deteriorated, and she was subsequently intubated. On day 6, VV-ECMO was introduced. Lopinavir/ritonavir was given; continuous renal replacement therapy was also introduced. On day 10, her chest radiography and lung compliance improved. She was weaned off ECMO on day 12. Conclusion: Treatment of severe pneumonia in COVID-19 by ECMO should recognize lung plasticity considering time to ECMO introduction and interstitial biomarkers. In Japan, centralization of ECMO patients has not been sufficient. Thus, we suggest nationwide centralization and further research to respond to the crisis caused by COVID-19.","Acute Med Surg","Taniguchi, Hayato","Ogawa, Fumihiro","Honzawa, Hiroshi","Yamaguchi, Keishi","Niida, Shoko","Shinohara, Mafumi","Takahashi, Kohei","Iwashita, Masayuki","Abe, Takeru","Kubo, Sousuke","Kudo, Makoto","Takeuchi, Ichiro","32313662"],"abstract":["Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is one of the ultimate treatments for acute respiratory failure. However, the effectiveness of ECMO in patients with novel coronavirus disease (COVID-19) is unknown. Case Presentation: A 72-year-old woman who was a passenger of a cruise ship tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while in quarantine on board using throat swab. Three days after admission, her condition deteriorated, and she was subsequently intubated. On day 6, VV-ECMO was introduced. Lopinavir/ritonavir was given; continuous renal replacement therapy was also introduced. On day 10, her chest radiography and lung compliance improved. She was weaned off ECMO on day 12. Conclusion: Treatment of severe pneumonia in COVID-19 by ECMO should recognize lung plasticity considering time to ECMO introduction and interstitial biomarkers. In Japan, centralization of ECMO patients has not been sufficient. Thus, we suggest nationwide centralization and further research to respond to the crisis caused by COVID-19."],"journal":"Acute Med Surg","authors":["Taniguchi, Hayato","Ogawa, Fumihiro","Honzawa, Hiroshi","Yamaguchi, Keishi","Niida, Shoko","Shinohara, Mafumi","Takahashi, Kohei","Iwashita, Masayuki","Abe, Takeru","Kubo, Sousuke","Kudo, Makoto","Takeuchi, Ichiro"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313662","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ams2.509","keywords":["coronavirus disease 2019","japan","extracorporeal membrane oxygenation","lopinavir","ritonavir","severe acute respiratory syndrome coronavirus 2"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Veno","Japan","Japan"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"e_drugs":["lopinavir-ritonavir drug combination"],"_version_":1664714520061280256,"score":397.36588},{"pmid":32251794,"title":"Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?","text":["Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO.","Int J Infect Dis","Hong, Xiaoyang","Xiong, Jing","Feng, Zhichun","Shi, Yuan","32251794"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO."],"journal":"Int J Infect Dis","authors":["Hong, Xiaoyang","Xiong, Jing","Feng, Zhichun","Shi, Yuan"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251794","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijid.2020.03.058","keywords":["acute respiratory distress syndrome","coronavirus disease 19","extracorporeal membrane oxygenation","respiratory failure"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352136203763712,"score":353.7062},{"pmid":32243266,"title":"Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.","text":["Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.","Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone. The role and outcome of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is currently unclear. Eight COVID-19 patients have received ECMO support in Shanghai with 7 with VV ECMO support and 1 VA ECMO during cardiopulmonary resuscitation. As of March 25, 2020, 4 patients died (50% mortality), three patients (37.5%) were successfully weaned off ECMO after 22, 40 days and 47 days support respectively, but remain on mechanical ventilation. One patient is still on VV ECMO with mechanical ventilation.The PaO2/FiO2 ratio before ECMO initiation were between 54 to 76 and all were well below 100. The duration of mechanical ventilation before ECMO ranged from 4-21 days. Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 to 47 days. In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes. ECMO support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise.","ASAIO J","Li, Xin","Guo, Zhen","Li, Bailing","Zhang, Xiaolin","Tian, Rui","Wu, Wei","Zhang, Zhongwei","Lu, Yunfei","Chen, Nan","Clifford, Sean P","Huang, Jiapeng","32243266"],"abstract":["Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone. The role and outcome of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is currently unclear. Eight COVID-19 patients have received ECMO support in Shanghai with 7 with VV ECMO support and 1 VA ECMO during cardiopulmonary resuscitation. As of March 25, 2020, 4 patients died (50% mortality), three patients (37.5%) were successfully weaned off ECMO after 22, 40 days and 47 days support respectively, but remain on mechanical ventilation. One patient is still on VV ECMO with mechanical ventilation.The PaO2/FiO2 ratio before ECMO initiation were between 54 to 76 and all were well below 100. The duration of mechanical ventilation before ECMO ranged from 4-21 days. Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 to 47 days. In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes. ECMO support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise."],"journal":"ASAIO J","authors":["Li, Xin","Guo, Zhen","Li, Bailing","Zhang, Xiaolin","Tian, Rui","Wu, Wei","Zhang, Zhongwei","Lu, Yunfei","Chen, Nan","Clifford, Sean P","Huang, Jiapeng"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243266","week":"202014|Mar 30 - Apr 05","doi":"10.1097/MAT.0000000000001172","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Shanghai","Shanghai","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638249381920770,"score":311.5692},{"pmid":32296808,"title":"Extracorporeal Membrane Oxygenation for Severe Respiratory Failure during Respiratory Epidemics and Pandemics: A Narrative Review.","text":["Extracorporeal Membrane Oxygenation for Severe Respiratory Failure during Respiratory Epidemics and Pandemics: A Narrative Review.","INTRODUCTION: Epidemics and pandemics from zoonotic respiratory viruses, such as the 2019 novel coronavirus, can lead to significant global intensive care burden as patients progress to acute respiratory distress syndrome (ARDS). A subset of these patients develops refractory hypoxaemia despite maximal conventional mechanical ventilation and require extracorporeal membrane oxygenation (ECMO). This review focuses on considerations for ventilatory strategies, infection control and patient selection related to ECMO for ARDS in a pandemic. We also summarize the experiences with ECMO in previous respiratory pandemics. METHODS: A review of pertinent studies was conducted via a search using MEDLINE, EMBASE and Google Scholar. References of articles were also examined to identify other relevant publications. RESULTS: Since the H1N1 Influenza pandemic in 2009, the use of ECMO for ARDS continues to grow despite limitations in evidence for survival benefit. There is emerging evidence to suggest that lung protective ventilation for ARDS can be further optimized while receiving ECMO so as to minimize ventilator-induced lung injury and subsequent contributions to multi-organ failure. Efforts to improve outcomes should also encompass appropriate infection control measures to reduce co-infections and prevent nosocomial transmission of novel respiratory viruses. Patient selection for ECMO in a pandemic can be challenging. We discuss important ethical considerations and predictive scoring systems that may assist clinical decision-making to optimize resource allocation. CONCLUSION: The role of ECMO in managing ARDS during respiratory pandemics continues to grow. This is supported by efforts to redefine optimal ventilatory strategies, reinforce infection control measures and enhance patient selection.","Ann Acad Med Singapore","Lim, Joel Kian Boon","Qadri, Syeda Kashfi","Toh, Theresa Shu Wen","Lin, Cheryl Bin","Mok, Yee Hui","Lee, Jan Hau","32296808"],"abstract":["INTRODUCTION: Epidemics and pandemics from zoonotic respiratory viruses, such as the 2019 novel coronavirus, can lead to significant global intensive care burden as patients progress to acute respiratory distress syndrome (ARDS). A subset of these patients develops refractory hypoxaemia despite maximal conventional mechanical ventilation and require extracorporeal membrane oxygenation (ECMO). This review focuses on considerations for ventilatory strategies, infection control and patient selection related to ECMO for ARDS in a pandemic. We also summarize the experiences with ECMO in previous respiratory pandemics. METHODS: A review of pertinent studies was conducted via a search using MEDLINE, EMBASE and Google Scholar. References of articles were also examined to identify other relevant publications. RESULTS: Since the H1N1 Influenza pandemic in 2009, the use of ECMO for ARDS continues to grow despite limitations in evidence for survival benefit. There is emerging evidence to suggest that lung protective ventilation for ARDS can be further optimized while receiving ECMO so as to minimize ventilator-induced lung injury and subsequent contributions to multi-organ failure. Efforts to improve outcomes should also encompass appropriate infection control measures to reduce co-infections and prevent nosocomial transmission of novel respiratory viruses. Patient selection for ECMO in a pandemic can be challenging. We discuss important ethical considerations and predictive scoring systems that may assist clinical decision-making to optimize resource allocation. CONCLUSION: The role of ECMO in managing ARDS during respiratory pandemics continues to grow. This is supported by efforts to redefine optimal ventilatory strategies, reinforce infection control measures and enhance patient selection."],"journal":"Ann Acad Med Singapore","authors":["Lim, Joel Kian Boon","Qadri, Syeda Kashfi","Toh, Theresa Shu Wen","Lin, Cheryl Bin","Mok, Yee Hui","Lee, Jan Hau"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296808","week":"202016|Apr 13 - Apr 19","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664641388431540224,"score":297.4332},{"pmid":32317557,"title":"Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.","text":["Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.","As COVID-19 cases surge worldwide, an urgent need exists to enhance our understanding of the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill patients with COVID-19 who develop acute respiratory and cardiac compromise refractory to conventional therapy. The purpose of this manuscript is to review our initial clinical experience in 32 patients with confirmed COVID-19 treated with ECMO.A multi-institutional registry and database was created and utilized to assess all patients who were supported with ECMO provided by SpecialtyCare. Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, specific medications utilized to treat COVID-19, and short-term outcomes through hospital discharge. This analysis includes all of our patients with COVID-19 supported with ECMO, with an analytic window starting March 17, 2020 when our first COVID-19 patient was placed on ECMO, and ending April 9, 2020.During the 24 days of this study, 32 consecutive patients with COVID-19 were placed on ECMO at 9 different hospitals. As of the time of analysis, 17 remain on ECMO, 10 died prior to or shortly after decannulation, and 5 are alive and extubated after removal from ECMO, with one of these 5 discharged from the hospital. Adjunctive medication in the surviving patients while on ECMO was as follows: 4 of 5 survivors received intravenous steroids, 3 of 5 survivors received antiviral medications (Remdesivir), 2 of 5 survivors were treated with anti-interleukin-6-receptor monoclonal antibodies (Tocilizumab or Sarilumab), and 1 of 5 survivors received hydroxychloroquine.An analysis of 32 COVID-19 patients with severe pulmonary compromise supported with ECMO suggests that ECMO may play a useful role in salvaging select critically ill patients with COVID-19. Additional patient experience and associated clinical and laboratory data must be obtained to further define the optimal role of ECMO in patients with COVID-19 and ARDS. These initial data may provide useful information to help define the best strategies to care for these challenging patients, and may also provide a framework for much-needed future research about the use of ECMO to treat patients with COVID-19.","ASAIO J","Jacobs, Jeffrey P","Stammers, Alfred H","St Louis, James","Hayanga, J W Awori","Firstenberg, Michael S","Mongero, Linda B","Tesdahl, Eric A","Rajagopal, Keshava","Cheema, Faisal H","Coley, Tom","Badhwar, Vinay","Sestokas, Anthony K","Slepian, Marvin J","32317557"],"abstract":["As COVID-19 cases surge worldwide, an urgent need exists to enhance our understanding of the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill patients with COVID-19 who develop acute respiratory and cardiac compromise refractory to conventional therapy. The purpose of this manuscript is to review our initial clinical experience in 32 patients with confirmed COVID-19 treated with ECMO.A multi-institutional registry and database was created and utilized to assess all patients who were supported with ECMO provided by SpecialtyCare. Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, specific medications utilized to treat COVID-19, and short-term outcomes through hospital discharge. This analysis includes all of our patients with COVID-19 supported with ECMO, with an analytic window starting March 17, 2020 when our first COVID-19 patient was placed on ECMO, and ending April 9, 2020.During the 24 days of this study, 32 consecutive patients with COVID-19 were placed on ECMO at 9 different hospitals. As of the time of analysis, 17 remain on ECMO, 10 died prior to or shortly after decannulation, and 5 are alive and extubated after removal from ECMO, with one of these 5 discharged from the hospital. Adjunctive medication in the surviving patients while on ECMO was as follows: 4 of 5 survivors received intravenous steroids, 3 of 5 survivors received antiviral medications (Remdesivir), 2 of 5 survivors were treated with anti-interleukin-6-receptor monoclonal antibodies (Tocilizumab or Sarilumab), and 1 of 5 survivors received hydroxychloroquine.An analysis of 32 COVID-19 patients with severe pulmonary compromise supported with ECMO suggests that ECMO may play a useful role in salvaging select critically ill patients with COVID-19. Additional patient experience and associated clinical and laboratory data must be obtained to further define the optimal role of ECMO in patients with COVID-19 and ARDS. These initial data may provide useful information to help define the best strategies to care for these challenging patients, and may also provide a framework for much-needed future research about the use of ECMO to treat patients with COVID-19."],"journal":"ASAIO J","authors":["Jacobs, Jeffrey P","Stammers, Alfred H","St Louis, James","Hayanga, J W Awori","Firstenberg, Michael S","Mongero, Linda B","Tesdahl, Eric A","Rajagopal, Keshava","Cheema, Faisal H","Coley, Tom","Badhwar, Vinay","Sestokas, Anthony K","Slepian, Marvin J"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317557","week":"202017|Apr 20 - Apr 26","doi":"10.1097/MAT.0000000000001185","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["remdesivir","sarilumab","tocilizumab","Steroids","Hydroxychloroquine"],"_version_":1664815087834103808,"score":274.08606}]}